checkmylabel.com

What It Is

Checkmylabel is a drug labeling compliance tool for pharmaceutical finished formulation manufacturers in India. It aims to automate a label content generation process that has traditionally relied on manual regulatory research, sample references, and expert judgment. The website emphasizes that Indian regulators frequently revise labeling rules and guidelines, and that manual handling can easily miss conditional requirements, potentially leading to legal risk as well as reprinting and rework costs.

Core Features and Capabilities

At its core, the product uses advanced AI algorithms and a machine-learning resource library to quickly generate the content that needs to be printed on pharmaceutical formulation labels based on basic product information provided by the user. The output is presented in an easy-to-implement checklist format. Features include label content generation, detailed explanations for each item, special warnings, product-specific warnings and labelling instructions, schedule applicable calculations for complex scenarios, and Banned FDCs alerts. The product is clearly designed around Indian pharmaceutical formulation labeling regulations and industry practice, and the team also mentions experience with government regulatory bodies and QC departments at large pharmaceutical companies.

Pricing, Deployment, and Enterprise Capabilities

The page does not disclose plans, pricing, billing methods, payment methods, or any clear free plan or trial policy. Although there is a “Try Now!” button, it is not possible to determine whether a free trial is available. Common enterprise software information such as third-party integrations, APIs, developer support, team collaboration, permission management, audit logs, data security certifications, cloud or self-hosted deployment is also not provided in the main content. For procurement by mid-sized and large pharmaceutical companies, it would therefore be necessary to request a product white paper, security documentation, service SLA, and clarification of compliance responsibility boundaries.

Pros and Cons

The main advantage is its highly vertical focus: it directly addresses the complexity of Indian pharmaceutical labeling compliance, frequent regulatory changes, and the high risk of manual errors. If its rule base and algorithms are accurate, it could significantly save senior QC staff time and reduce the risk of label rework. The checklist-style output should also make it easier to incorporate into design and review workflows. The downside is the lack of public transparency, especially around pricing, security, deployment, integrations, and permission systems. Its scope also appears to be highly limited to Indian pharmaceutical formulation labeling regulations, with unclear applicability to other countries or other types of medical products.

Who It’s For and Access from China

It is best suited to manufacturers, regulatory affairs teams, QC teams, and companies that produce or sell pharmaceutical formulations in the Indian market and need to frequently generate or review label content. If a Chinese company only needs to comply with China’s NMPA regulations, the tool does not indicate support for Chinese regulatory requirements and should be evaluated cautiously. Access from China cannot be determined from the page; network connectivity, payment methods, and local alternatives would all need to be tested. In China, possible alternatives include pharmaceutical regulatory databases, label compliance consulting services, or internal compliance management systems designed around NMPA requirements.